Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos Principais

Visualizar Toda a Documentação

A1340000

Atenolol

European Pharmacopoeia (EP) Reference Standard

Sinônimo(s):

(±)-4-[2-Hydroxy-3-[(1-methylethyl)amino]propoxy]benzeneacetamide, 4-[2′-Hydroxy-3′-(isopropylamino)propoxy]phenylacetamide

Faça loginpara ver os preços organizacionais e de contrato
Todas as fotos(1)

About This Item

Fórmula empírica (Notação de Hill):
C14H22N2O3
Número CAS:
29122-68-7
Peso molecular:
266.34
Número CE:
249-451-7
Número MDL:
MFCD00057645
Código UNSPSC:
41116107
ID de substância PubChem:
329770360
NACRES:
NA.24

grau

pharmaceutical primary standard

família API

atenolol

fabricante/nome comercial

EDQM

aplicação(ões)

pharmaceutical (small molecule)

Formato

neat

temperatura de armazenamento

2-8°C

cadeia de caracteres SMILES

CC(C)NCC(O)COc1ccc(CC(N)=O)cc1

InChI

1S/C14H22N2O3/c1-10(2)16-8-12(17)9-19-13-5-3-11(4-6-13)7-14(15)18/h3-6,10,12,16-17H,7-9H2,1-2H3,(H2,15,18)

chave InChI

METKIMKYRPQLGS-UHFFFAOYSA-N

Informações sobre genes

human ... ADRB1(153)

Procurando produtos similares? Visita Guia de comparação de produtos

Categorias relacionadas

Descrição geral

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicação

Atenolol EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Embalagem

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Outras notas

Sales restrictions may apply.

produto relacionado

Nº do produto
Descrição
Preços

1044403

Atenolol, United States Pharmacopeia (USP) Reference Standard

Y0001089

Atenolol for system suitability, European Pharmacopoeia (EP) Reference Standard

PHR1909

Atenolol, Pharmaceutical Secondary Standard; Certified Reference Material

BP370

Atenolol impurity standard, British Pharmacopoeia (BP) Reference Standard

BP492

Atenolol, British Pharmacopoeia (BP) Reference Standard

1044367

Atenolol Related Compound F, United States Pharmacopeia (USP) Reference Standard

1044265

Atenolol Related Compound B, United States Pharmacopeia (USP) Reference Standard

1044254

Atenolol Related Compound A, United States Pharmacopeia (USP) Reference Standard

1044276

Atenolol Related Compound C, United States Pharmacopeia (USP) Reference Standard

1044298

Atenolol Related Compound E, United States Pharmacopeia (USP) Reference Standard

1044287

Atenolol Related Compound D, United States Pharmacopeia (USP) Reference Standard

Código de classe de armazenamento

11 - Combustible Solids

Classe de risco de água (WGK)

WGK 2

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable

Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number

Lamentamos, não temos COA para este produto disponíveis online no momento.

Se precisar de ajuda, entre em contato Atendimento ao cliente

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Sripal Bangalore et al.
The American journal of medicine, 127(10), 939-953 (2014-06-15)
Debate exists about the efficacy of β-blockers in myocardial infarction and their required duration of usage in contemporary practice. We conducted a MEDLINE/EMBASE/CENTRAL search for randomized trials evaluating β-blockers in myocardial infarction enrolling at least 100 patients. The primary outcome
Ronald V Lacro et al.
The New England journal of medicine, 371(22), 2061-2071 (2014-11-19)
Aortic-root dissection is the leading cause of death in Marfan's syndrome. Studies suggest that with regard to slowing aortic-root enlargement, losartan may be more effective than beta-blockers, the current standard therapy in most centers. We conducted a randomized trial comparing
H Sakurai et al.
Japanese circulation journal, 64(11), 893-896 (2000-12-08)
Cardiogenic shock developed in a 72-year-old Japanese woman during combination therapy with verapamil and atenolol for recurrent supraventricular arrhythmia. She had coronary atherosclerosis, liver cirrhosis and bradycardia-tachycardia syndrome. Despite of the high-dose catecholamines and counterpulsation, she progressively deteriorated. Bolus administration
Atenolol: pharmacokinetic/dynamic aspects of comparative developmental toxicity.
Sonia A Tabacova et al.
Reproductive toxicology (Elmsford, N.Y.), 16(1), 1-7 (2002-04-06)
Laura M Kuyper et al.
The Canadian journal of cardiology, 30(5 Suppl), S47-S53 (2014-04-23)
Previous reviews have shown that β-blocker use for the treatment of hypertension without compelling indications was associated with increased risk of stroke in the elderly. It remains unclear whether this increased risk was driven by the type of β-blocker. We
Exibir todos os documentos relacionados

Artigos

TLC Silica Gel 60 G Plates with Gypsum

TLC plates, with silica gel, gypsum as binder, International Pharmacopoeia compliant, for identification of Atenolol and Chlorthalidone in tablets

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica